Exploratory analysis of gut microbiome as a novel biomarker in patients with advanced thymic carcinoma on immunochemotherapy

Exploratory analysis of gut microbiome as a novel biomarker in patients with advanced thymic carcinoma on immunochemotherapy - NCCH2109A

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053154

Enrollment

Registered

2023-12-19

Start date

2024-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thymic carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Written consent to participate in this accessory study has been obtained prior to the start of protocol treatment in the main study (NCCH2109).

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Whether the composition of the intestinal flora is a predictive factor	—

Secondary

Measure	Time frame
Whether plasma biomarkers are predictive factors	—

Countries

Japan

Contacts

Public ContactYusuke Okuma

National Cancer Center Hospital Department of thoracic oncology

ncch2109_jimukyoku@is-pc.or.jp03-3542-2511

Outcome results